Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Jason Scott Starr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4922-1392; OpenAlex author ID A5043086563. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  2. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1200/op.23.00447↗
  3. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Last author DOI 10.1200/po.22.00706↗
  4. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  5. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing. Co-author DOI 10.7759/cureus.37239↗
  6. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. Co-author DOI 10.1136/jitc-2021-004485↗
  7. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  8. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mohamad Bassam Sonbol · 4 shared papers, 2021–2023 · strength 0.55
  2. Tanios Bekaii‐Saab · 4 shared papers, 2021–2023 · strength 0.55
  3. Hani M. Babiker · 3 shared papers, 2023 · strength 0.54
  4. Tucker W. Coston · 2 shared papers, 2023 · strength 0.38
  5. Mitesh J. Borad · 3 shared papers, 2021–2023 · strength 0.37
  6. Daniel H. Ahn · 3 shared papers, 2021–2023 · strength 0.37
  7. John Andrew Stauffer · 2 shared papers, 2023 · strength 0.33
  8. Sakti Chakrabarti · 2 shared papers, 2022–2023 · strength 0.32
  9. Umair Majeed · 2 shared papers, 2021–2023 · strength 0.27
  10. Pashtoon Murtaza Kasi · 2 shared papers, 2021–2022 · strength 0.26
  11. Gehan Botrus · 2 shared papers, 2021 · strength 0.21
  12. Kabir Mody · 2 shared papers, 2021 · strength 0.21
  13. Pedro Luiz Serrano Usón · 2 shared papers, 2021 · strength 0.21
  14. Zev A. Wainberg · 1 shared paper, 2025 · strength 0.21
  15. Ashwin Reddy Sama · 1 shared paper, 2025 · strength 0.21
  16. Jonathan J. Hue · 1 shared paper, 2025 · strength 0.21
  17. Andre Alabd · 1 shared paper, 2025 · strength 0.21
  18. Kavin Sugumar · 1 shared paper, 2025 · strength 0.21
  19. Anup Kasi · 1 shared paper, 2025 · strength 0.21
  20. Hedy Lee Kindler · 1 shared paper, 2025 · strength 0.21
  21. Lei Zheng · 1 shared paper, 2025 · strength 0.21
  22. Jordan Michael Winter · 1 shared paper, 2025 · strength 0.21
  23. Bhrugun Anisetti · 1 shared paper, 2023 · strength 0.20
  24. Himil J Mahadevia · 1 shared paper, 2023 · strength 0.20
  25. Thomas P. Potjer · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.